Recently, it has been proposed that AD be staged into initial, early, intermediate, or advanced stages based on the presence of β-amyloid (Aβ) and the topographic extent and magnitude of tau aggregation using both Aβ and tau PET. The gene discussed is MAPT; the disease is Alzheimer disease.